Fig. 4: CTCs-derived xenograft and in vitro cultures are relevant models for drug testing.
From: Circulating tumour cell-derived xenograft as a preclinical platform for metastatic breast cancer
a Schematic workflow of drug treatment in in vitro 3D cell culture. Created in https://BioRender.com. b Analysis of spheroids’ viability at the endpoint using CellTitre Glo ATP assay. The data are presented as fold of control (vehicle treatment) at the endpoint (21 days), as a mean ± SEM from two independent repetitions performed in technical multiplicate. c Schematic workflow of mice treatment with carboplatin (CBDCA) and vandetanib (VANDE). Created in https://BioRender.com. d Normalised tumour volume after weekly intraperitoneal treatment with carboplatin (50 mg/kg), and daily treatment with vandetanib (25 mg/kg) via oral gavage for 21 days. Data represent mean ± SEM from two independent repetitions. e Tumour weight at the endpoint of the in vivo experiment. Data represent mean ± SEM from two independent repetitions. Statistical analysis was performed with the Mann-Whitney non-parametric test.
